Elite Wealth Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-5,573
Closed -$204K 50
2023
Q2
$204K Sell
5,573
-375
-6% -$14.6K 0.02% 48
2023
Q1
$243K Hold
5,948
0.01% 51
2022
Q4
$305K Buy
5,948
+175
+3% +$8.39K 0.03% 45
2022
Q3
$253K Hold
5,773
0.02% 43
2022
Q2
$303K Buy
5,773
+200
+4% +$10.2K 0.05% 43
2022
Q1
$289K Sell
5,573
-10
-0.2% -$519 0.05% 47
2021
Q4
$330K Buy
+5,583
New +$277K 0.05% 46
2018
Q4
Sell
-4,929
Closed -$206K 50
2018
Q3
$206K Sell
4,929
-1,054
-18% -$40.6K 0.04% 47
2018
Q2
$206K Hold
5,983
0.07% 48
2018
Q1
$201K Sell
5,983
-105
-2% -$3.61K 0.16% 54
2017
Q4
$209K Buy
+6,088
New +$208K 0.18% 56
2016
Q3
$164K Buy
+5,106
New +$171K 0.27% 43
2015
Q4
Sell
-18,458
Closed -$550K 54
2015
Q3
$550K Buy
+18,458
New +$592K 0.87% 44
2014
Q4
Sell
-4,933
Closed -$138K 355
2014
Q3
$138K Buy
4,933
+2,182
+79% +$61.2K 0.12% 77
2014
Q2
$77K Sell
2,751
-2,540
-48% -$72.4K 0.08% 90
2014
Q1
$161K Sell
5,291
-28,916
-85% -$862K 0.13% 72
2013
Q4
$994K Sell
34,207
-91,303
-73% -$2.66M 0.73% 40
2013
Q3
$3.42M Buy
125,510
+86,808
+224% +$2.36M 3.02% 5
2013
Q2
$1.03M Buy
+38,702
New +$1.07M 1.51% 7

Other funds holding PFE

Elite Wealth Management's PFE Position: Q3 2023 in Review

Elite Wealth Management sold out of Pfizer (PFE) in Q3 2023, closing a stake of 5,573 shares — an estimated $204K sold.

Elite Wealth Management first reported a position in PFE in Q2 2013 and held it in 19 quarters. The position peaked at $3.42M in Q3 2013. 2,926 funds tracked by Wall St. Rank hold PFE as of Q3 2023.

  • Elite Wealth Management reported no remaining Pfizer position as of Q3 2023 after selling out during the quarter.
  • Elite Wealth Management sold 5,573 Pfizer shares in Q3 2023, an estimated $204K.
  • Elite Wealth Management first reported a position in Pfizer in Q2 2013 and held it in 19 quarters.
  • Elite Wealth Management's Pfizer position peaked at $3.42M in Q3 2013.
  • 2,926 funds tracked by Wall St. Rank held Pfizer as of Q3 2023.

Based on Elite Wealth Management's 13F filing for Q3 2023, filed 1 Nov 2023.